Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar

FDA Pushed Back On Initial BLA Filing Earlier This Year

 
• By Chloe Kent
  
Watering can watering money trees
Analysts have described Xbrane as a hidden gem. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin